hackettg

As part of our Funding & Reimbursement Shorts series Community Pharmacy England’s in-house Drug Tariff and funding experts have created a new video providing guidance on how handling ‘FS’ endorsed prescriptions for free supply of sexual health treatments. In our latest video, Mitesh Bhudia and Gemma Hackett from our Dispensing and Supply Team, discuss the [...]

The post Funding & Reimbursement Shorts: ‘FS’ endorsed prescriptions for free supply of sexual health treatments appeared first on Community Pharmacy England.

The Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 February 2025. Key g Special container – This product is a special container and should be dispensed in its complete original pack size. n Item requiring reconstitution [...]

The post Drug Tariff Watch – February 2025 appeared first on Community Pharmacy England.

The Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 January 2025. From 1 January 2025, Original Pack Dispensing (+/-10% OPD) rules have been introduced in The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) (No. 2) [...]

The post Drug Tariff Watch – January 2025 appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Information: Oxybutynin hydrochloride 2.5 mg/5 ml Oral Solution (Brillpharma Limited) Drug alert number: EL (24)A/61 Date issued: 4 December 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Oxybutynin hydrochloride 2.5 mg/5 ml Oral Solution (Brillpharma Limited) DMRC reference number:DMRC-34033472 Company [...]

The post MHRA Class 4 Medicines Defect Information: Oxybutynin hydrochloride 2.5 mg/5 ml Oral Solution (Brillpharma Limited) appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Information: Mycophenolate Mofetil 1g/5ml Oral Suspension (Rosemont Pharmaceuticals Limited) Drug alert number: EL (24)A/59 Date issued: 2 December 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Mycophenolate Mofetil 1g/5ml Oral Suspension (Rosemont Pharmaceuticals Limited) DMRC reference number: DMRC-33616486 Company name: [...]

The post MHRA Class 4 Medicines Defect Information: Mycophenolate Mofetil 1g/5ml Oral Suspension (Rosemont Pharmaceuticals Limited) appeared first on Community Pharmacy England.